COR's MWI Animal Health to Merge With Covetrus in $3.5 Billion Deal
Cencora is set to merge MWI Animal Health with Covetrus in a $3.5B deal, retaining a 34.3% stake as it unlocks capital and targets animal health growth.
Cencora's animal health unit to merge with Covetrus in $3.5 billion deal
Drug distributor Cencora will merge its MWI Animal Health unit with privately held Covetrus in a deal that values MWI at $3.5 billion, the companies said on Wednesday.
Is the Options Market Predicting a Spike in Cencora Stock?
Investors need to pay close attention to COR stock based on the movements in the options market lately.
Cencora Stock Down Despite Q1 Earnings Beat, Gross Margin Improves
COR shares slip despite Q1 EPS beat and revenues match estimates, margins expand and fiscal 2026 growth guidance up.
Cencora (COR) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Cencora (COR) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Cencora (COR) Q1 Earnings Top Estimates
Cencora (COR) came out with quarterly earnings of $4.08 per share, beating the Zacks Consensus Estimate of $4.07 per share. This compares to earnings of $3.73 per share a year ago.
Exploring Analyst Estimates for Cencora (COR) Q1 Earnings, Beyond Revenue and EPS
Besides Wall Street's top-and-bottom-line estimates for Cencora (COR), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.
Can Specialty and International Momentum Support Cencora's Q1 Results?
COR's Q1 outlook is supported by specialty utilization, RCA momentum, and steady international growth, even as GLP-1 tailwinds ease.
Cencora: High-Growth Specialty Services Firm Disguised As A Distributor
Cencora is transforming from a low-margin distributor to a higher-margin specialty services and oncology-focused business, underrecognized by the market. Cencora's acquisition of OneOncology is a transformational event, prompting raised long-term EPS growth guidance to 10-14% and signaling structurally higher margins. Recent results show robust U.S. segment performance, with Q4 operating income up 25.1%, and fiscal 2026 guidance projecting 8-10% operating income growth.
Cencora, Inc. (COR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Cencora, Inc. (COR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Why Cencora (COR) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why You Should Retain Cencora Stock in Your Portfolio Now
Cencora's strength in U.S. Healthcare Solutions, along with rising specialty drug demand and biosimilar adoption, supports growth, though competitive pressures and international weakness remain headwinds.
